All In Biotech

Free tool

FAERS Monitor: Exelderm

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018737 or its brand name (Exelderm, Sulconazole Nitrate). Reports on generic versions are filed under their own applications.

Reports

23

Serious

13

57% of reports

Hospitalization

8

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective3
  • anxiety2
  • erythema2
  • fatigue2
  • generalised pustular psoriasis2
  • herpes zoster2
  • hypotension2
  • nausea2
  • pruritus2
  • abnormal dreams1
  • acute kidney injury1
  • altered state of consciousness1
  • asthenia1
  • atrial fibrillation1
  • basal cell carcinoma1

Reports by year received

View as table
YearReports
20062
20071
20131
20141
20153
20162
20172
20191
20202
20212
20233
20252
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,136 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
generalised pustular psoriasis26356.91682.47,099
basal cell carcinoma158.68.614
altered state of consciousness142.26.210
abnormal dreams133.14.97
herpes zoster231.88.533
atrial fibrillation19.41.41
hypotension29.12.48
erythema28.92.47
anxiety26.41.75
acute kidney injury16.00.91
pruritus24.81.33
asthenia12.40.40
fatigue22.30.61
nausea22.30.60
drug ineffective32.10.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.